title: Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease.
abstract: OBJECTIVE
  The aim of this study was to determine the ability of 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography (FDG-PET) to predict the clinical outcome of previously treated patients with Hodgkin's Disease (HD).
  
  
  METHODS
  Thirty-two patients were studied with PET within a median interval of 5.2 months after treatment. Conventional imaging (CI) performed within two months before PET included 2.9+/-1.2 imaging tests/patient. To determine the independent ability of FDG-PET to predict the clinical outcome, PET images were reread without knowledge of CI and clinical history. Study end points were disease-free survival, or clinical evidence of disease or death. PET and CI stages were also compared for each patient.
  
  
  RESULTS
  Using the clinical outcome as gold standard after a median follow-up of 14 months, 21 of 32 patients (65%) were considered disease-free while 11 of 32 patients (35%) had evidence for disease or had died. The predictive accuracy of PET was 91% vs. 66% for conventional imaging (P<0.05). The positive predictive value (PPV) was also significantly higher for PET (79% vs. 50%, P<0.05), while its negative predictive value (NPV) tended to be higher than that of CI (100% vs. 86%, P=0.08). Kaplan-Meier analysis for disease-free survival showed a significant difference between PET-negative and -positive results. No such difference was observed between CI-positive and -negative results (P=0.35).
  
  
  CONCLUSIONS
  Whole-body FDG-PET imaging modified the clinical stage in 28% of patients. Moreover, FDG-PET predicted patient outcome with a higher predictive accuracy than CI. This superior prognostic accuracy was achieved with a single FDG-PET study vs. 2.9+/-1.2 CI procedures/patient.
authors.affiliation: Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, UCLA School of Medicine, Los Angeles, CA, USA.
authors.forename: Jean-Emmanuel
authors.initials: JE
authors.lastname: Filmont
authors.forename: Cecelia S
authors.initials: CS
authors.lastname: Yap
authors.forename: Fred
authors.initials: F
authors.lastname: Ko
authors.forename: Duska
authors.initials: D
authors.lastname: Vranjesevic
authors.forename: Andrew
authors.initials: A
authors.lastname: Quon
authors.forename: Daniel J A
authors.initials: DJ
authors.lastname: Margolis
authors.forename: Arash
authors.initials: A
authors.lastname: Safaei
authors.forename: Christos
authors.initials: C
authors.lastname: Emmanouilides
authors.forename: Daniel H S
authors.initials: DH
authors.lastname: Silverman
authors.forename: Michael E
authors.initials: ME
authors.lastname: Phelps
authors.forename: Johannes
authors.initials: J
authors.lastname: Czernin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000628:therapy; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D014055:Tomography, Emission-Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18